Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allozyne Inc.

www.allozyne.com

Latest From Allozyne Inc.

BioNotebook: Merck drops Ariad's ridaforolimus; United Therapeutics, Infinity, Verastem updates; Dipexium, Achaogen IPO terms

Ariad will regain ridaforolimus rights from Merck in November; United Therapeutics considers deals, protects patents; Infinity secures new debt; Verastem buys back VS-4718 rights; and Dipexium, Achaogen set IPO terms.

Cardiovascular Cancer

Money talks: Verastem leverages IPO to build cancer stem cell pipeline

Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.

Cancer

Antibody-Drug Conjugates: The Next Generation Of Moving Parts

The next generation of antibody-drug conjugates have much room for improvement: engineered proteins, drugs, the linkers that bond them together, and perhaps even new targets to attack. All their complexity is an invitation to innovation, but will the parts come together into products that prove safe and efficacious in the clinic?

BioPharmaceutical Strategy

Moribund Poniard outlicenses focal adhesion kinase (FAK) before merger with Allozyne

Poniard Pharmaceuticals, which is hoping to provide a way out for shareholders and complete a merger with privately held Allozyne before the end of 2011, has granted an undisclosed party the worldwide rights to its focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allozyne Inc.
  • Senior Management
  • Meenu Chhabra, Pres. & CEO
    Kenneth Grabstein, PhD, CSO
  • Contact Info
  • Allozyne Inc.
    Phone: (206) 518-5700
    1600 Fairview Ave. E
    Ste. 300
    Seattle, WA 98102
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register